GlassScriptPhysician profile
Amy E Shirer
NPI 1598085524
$4,503.45
in general payments reported to CMS, 2019-2025
35 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $401 · 2021: $463 · 2022: $336 · 2023: $735 · 2024: $545 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $585.40 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $535.04 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $515.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $396.66 | 2019-2023 | Trintellix |
| Novo Nordisk INC | $390.48 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $265.83 | 2021-2025 | Ubrelvy, Vraylar |
| Kowa Pharmaceuticals America, INC. | $261.14 | 2019-2020 | |
| Pfizer INC. | $252.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $209.50 | 2019-2025 | Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $164.05 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.40 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $83.75 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $73.24 | 2020-2025 | Veozah |
| Abbott Laboratories | $66.83 | 2022 | |
| Azurity Pharmaceuticals, INC. | $45.75 | 2023-2024 | Horizant, Horizant |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $39.19 | 2023-2024 | Rexulti |
| Acella Pharmaceuticals, LLC | $38.10 | 2024-2025 | NP Thyroid 60 |
| Sanofi-Aventis U.S. LLC | $37.68 | 2019-2021 | |
| Amgen INC. | $36.01 | 2019-2025 | Repatha, Otezla |
| Genentech USA, INC. | $35.44 | 2019-2021 | |
| Allergan, INC. | $33.19 | 2020 | |
| Inspire Medical Systems, INC. | $32.58 | 2023 | Inspire |
| Ironwood Pharmaceuticals, INC | $30.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.63 | 2019 | |
| Hologic Sales and Service, LLC | $23.92 | 2025 | Thinprep 2000 Processor |
| Dexcom, INC. | $21.59 | 2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $18.29 | 2025 | Intellis Adaptivestim |
| Radius Health, INC. | $17.98 | 2024 | Tymlos |
| Lundbeck LLC | $17.12 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $16.60 | 2024-2025 | Voquezna |
| Currax Pharmaceuticals LLC | $15.84 | 2024 | Onzetra Xsail, Contrave |
| Sunovion Pharmaceuticals INC. | $14.76 | 2022 | |
| Esperion Therapeutics, INC. | $14.44 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.87 | 2019 | |
| Amarin Pharma, INC. | $13.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Shirer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.